Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, David Cairns, MSc, PhD, John R Jones, MD, Bhuvan Kishore, MB BS, MRCP, FRCPath, Mamta Garg, MD FRCP, FRCPath, Cathy Williams, MD MRCP, FRCPath, Kamaraj Karunanithi, MD FRCPath, Jindriska Lindsay, MD, MRCP, FRCPath, Nigel H. Russell, MD, Matthew Jenner, MBBS, MRCP, FRCPath, Gordon Cook, MB ChB, PhD FRCP(Glas), FRCPath, Mark T Drayson, MB ChB, PhD FRCPath, Roger G. Owen, MD, Walter M Gregory, PhD, Martin F. Kaiser, Faith E. Davies, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 1910.

https://doi.org/10.1182/blood-2019-126160

Published: 2019

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 436.

https://doi.org/10.1182/blood.V130.Suppl_1.436.436

Published: 2017

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Blood (2017) 130 (Supplement 1): 1854.

https://doi.org/10.1182/blood.V130.Suppl_1.1854.1854

Published: 2017

Journal Articles

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

Blood (2017) 130 (Supplement 1): 510.

https://doi.org/10.1182/blood.V130.Suppl_1.510.510

Published: 2017

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 1981.

https://doi.org/10.1182/blood.V126.23.1981.1981

Published: 2015

Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD

Blood (2015) 126 (23): 394.

https://doi.org/10.1182/blood.V126.23.394.394

Published: 2015

Journal Articles

Velcade, Vorinostat and Dexamethasone (V 2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial

Matthew W Jenner, MD, Avie-Lee Tillotson, Sarah R Brown, Louise M Flanagan, Debbie Sherratt, Charlotte Pawlyn, MB BChir, Cathy Williams, Faith E Davies, MD

Blood (2015) 126 (23): 1852.

https://doi.org/10.1182/blood.V126.23.1852.1852

Published: 2015

NARROW

Lenalidomide Induction and Maintenance Maximizes Outcome for Newly Diagnosed Transplant Eligible Myeloma Patients Irrespective of Risk Status: Long-Term Follow-up of the Myeloma XI Trial

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Lenalidomide Maintenance Significantly Improves Outcomes Compared to Observation Irrespective of Cytogenetic Risk: Results of the Myeloma XI Trial

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Continuous Treatment with Lenalidomide Improves Outcomes in Newly Diagnosed Myeloma Patients Not Eligible for Autologous Stem Cell Transplant: Results of the Myeloma XI Trial

Daratumumab Monotherapy for Patients with Intermediate or High-Risk Smoldering Multiple Myeloma (SMM): Centaurus, a Randomized, Open-Label, Multicenter Phase 2 Study

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Velcade, Vorinostat and Dexamethasone (V 2 D) in Relapsed Myeloma: Results of the Phase 2 Muk Four Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only